Suma Krishnan, President, R&D at Krystal Biotech, Inc. (KRYS), sold 76,952 shares at $85.55 ($6.7M) on 2023-04-17, disclosed to the SEC on 2023-04-18.
Scheduled sale ($6.7M) by President, R&D under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Negative factors outweigh the positive ones.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $85.55 | 1,050 | $90K | 1.3% |
| 2 | $85.55 | 1,050 | $90K | 1.3% |
| 3 | $86.80 | 4,298 | $373K | 5.5% |
| 4 | $86.80 | 4,297 | $373K | 5.5% |
| 5 | $86.80 | 4,297 | $373K | 5.5% |
| 6 | $86.80 | 4,298 |
| $373K |
| 5.5% |
| 7 | $87.41 | 9,429 | $824K | 12.2% |
| 8 | $87.41 | 9,428 | $824K | 12.2% |
| 9 | $87.41 | 9,428 | $824K | 12.2% |
| 10 | $87.41 | 9,429 | $824K | 12.2% |
| 11 | $88.41 | 9,724 | $860K | 12.8% |
| 12 | $88.41 | 9,724 | $860K | 12.8% |
| 13 | $89.12 | 500 | $45K | 0.7% |
| Total | $87.49 avg | 76,952 | $6.7M | 100% |
| Filing → |
| KRYS | SELL | 2026-03-06 | $13.2M | — | Filing → |
| KRYS | SELL | 2025-12-05 | $20.9M | — | Filing → |
| KRYS | SELL | 2025-07-16 | $10.1M | — | Filing → |